Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Set To Pass Six-Month Funding Bill, As Sequestration Still Looms

This article was originally published in The Gray Sheet

Executive Summary

Both the pending continuing resolution legislation and the sequestration have potential implications, not only for the funding FDA receives from Congress, but also for contributions from industry user fees.

You may also be interested in...



User Fee Limbo: FDA Will Not Have Access To Extra Industry Funds At FY 2013 Start

The new fiscal year starts Oct. 1, but FDA will not be able to spend the full amount of fiscal year 2013 industry user fees as a result of an emergency spending bill, and Congress is not expected to fix the issue until after the election in November at the earliest.

BD's Vince Forlenza Highlights Sequestration Threat To MedTech Research

At a Sept. 20 event in Washington, D.C., Becton Dickinson President and CEO Vince Forlenza said biomedical progress would be undermined by sequestration cuts to the National Institutes of Health. Meanwhile, a new poll shows many Americans oppose cutting medical research.

Sequestration Threat Looms For 2013 Health Care Spending

A report from Sen. Tom Harkin states that impending across-the-board cuts would lead to major NIH grants reduction, in addition to significant spending cuts for cancer and HIV screening.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel